Health
Dapagliflozin Misses Early Mark in COVID-19, but Kosiborod Sees Reasons for More Study – AJMC.com Managed Markets Network
The Dapagliflozin in Respiratory Failure in Patients With COVID-19 trial is the first phase 3 study to examine whether this SGLT2 inhibitor, which has proven effective…
A study that misses its mark would not typically generate this much interest, especially after trial sponsor AstraZeneca announced last month that results fell short of statistical significance. But with SGTL2 inhibitors gaining indications in heart failure and CKD, along with their original T2D approvalsconditions that put patients in danger when they get COVID-19many suspect this weekends results will not be the last word.
Since Kosiborod is one of the worlds leading experts on SGLT2 inhibitors,…
-
General14 hours agoQueensland announced as 2027 Women’s Softball World Cup host in first Australian event since 1965
-
Noosa News16 hours agoInquest into Rosemarie Campbell’s death three days after gastric bypass surgery hears of ‘massive loss’ to family
-
Noosa News8 hours agoReubhan Ralph identified as man behind terrifying childcare centre incident in Peregian Springs on the Sunshine Coast
-
General23 hours agoIndonesia airdropped aid for Palestinians in Gaza, but experts question its effectiveness